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Available online 28 August 2016Objective. The objective of the present study was to provide genomic and transcriptomic information that
may improve clinical outcomes for locally advanced cervical cancer (LACC) patients by searching for therapeutic
targets or potential biomarkers through the analysis of signiﬁcantly altered signaling pathways in LACC.
Methods.Microarray-based transcriptome proﬁling of 89 tumor samples from women with LACC was per-
formed. Through Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis, signiﬁcantly over-expressed
genes in LACC were identiﬁed; these genes were validated by quantitative reverse transcription-polymerase
chain reaction in an independent cohort, and the protein expression datawere obtained from theHuman Protein
Atlas.
Results. A transcriptome analysis revealed 7530 signiﬁcantly over-expressed genes in LACC samples. By KEGG
analysis, we found 93 dysregulated signaling pathways, including the JAK-STAT, NOTCH and mTOR-autophagy
pathways, which were signiﬁcantly upregulated. We conﬁrmed the overexpression of the relevant genes of
each pathway, such as NOTCH1, JAK2, STAM1, SOS1, ADAM17, PSEN1, NCSTN, RPS6, STK11/LKB1 and MLTS8/
GBL in LACC compared with normal cervical tissue epithelia.
Conclusions. Through comprehensive genomic and transcriptomic analyses, this work provides information
regarding signaling pathwayswith promising therapeutic targets, suggesting novel target therapies to be consid-
ered in future clinical trials for LACC patients.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Locally advanced cervical cancer
Genomic and transcriptome analysis
Therapeutic targets1. Introduction
Cervical cancer (CC) is the fourth most common cause of death in
women worldwide, with approximately 527,600 new cases and
265,700 deaths in 2012 [1] In developing countries, such as in Latin
America, sub-Saharan Africa and the Indian subcontinent, it is theología, Av. San Fernando22, Col.
o.
encia).
. This is an open access article undersecond most common cause of cancer death in women as a result of
more advanced disease at the time of diagnosis [2].
Persistent human papillomavirus (HPV) infection that has been
linked to cervical carcinogenesis promotes profound changes in the
transcriptional programs of epithelial cells, affecting complete signaling
pathways [3]. The study of genomic information that allows us to ana-
lyze signaling pathways with promising therapeutic targets on CC de-
serves further and deep investigation. Recently, several targeted
therapies have been developed to block speciﬁc signaling pathways,
such as the JAK-STAT pathway (Ruxolitinib, Fedratinib andthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
407A.D. Campos-Parra et al. / Gynecologic Oncology 143 (2016) 406–413tocilizumab), the Notch pathway (RO4929097, MK-0752, Anti-DLL4
mAb, OMP-21 M18 and OMP-59R) and the mTOR-autophagy pathway
(sirolimus, temsirolimus, everolimus and ridaforolimus) [4–6]. These
targeted therapies could improve the clinical outcome for up to 50% of
patients with locally advanced cervical cancer (LACC) who failed initial
treatment or those with recurrent disease [2,7].
The main goal of this study was to provide genomic information to
improve clinical outcome in LACC patients by searching for therapeutic
targets or potential biomarkers through the analysis of signaling path-
ways signiﬁcantly altered in LACC. To achieve this goal, we analyzed
the entire microarray-based transcriptome of 89 LACC tumor samples
compared with normal cervix epithelia. Next, using bioinformatics
tools to visualize the expression data in the context of pathway maps
for cellular function (Kyoto Encyclopedia of Genes and Genomes,
KEGG), we determined that the JAK-STAT, NOTCH and mTOR-autopha-
gy signaling pathways were signiﬁcantly upregulated. The expression
levels of most of the over-expressed relevant genes were validated in
an independent CCLA cohort and were compared with normal cervical
tissues epithelia. Moreover, the protein expression was evaluated, and
histopathological specimens were assessed to conﬁrm the microarray
results. These ﬁndings revealed new insights concerning LACC biology
and the importance of upregulated signaling pathways that might be
possibly blocked therapeutically.
2. Methods
2.1. Cervical samples
Cervical cancer tumors from 109 patients were obtained from 2010
to 2013 from the National Cancer Institute, Mexico City (INCan). All pa-
tients signed the informed consent form that was approved by the Eth-
ical and Scientiﬁc committees of INCan (015/012/IBI-CEI/961/15).
Immediately after surgical excision, the tumor biopsies were divided
into two pieces: one for pathological conﬁrmation and another for
nucleic acid isolation.
Sixteen non-pathological cervical tissues were obtained from pa-
tients who had undergone a hysterectomy by uterine myomas. The in-
clusion criteria were as follows: a) no previous cervical surgery (such
as the loop electrosurgical excision procedure or cone biopsy); b) no
HPV infection; c) no hormonal treatment; and d) three previous nega-
tive Pap smears.
2.2. RNA puriﬁcation and microarray hybridization
The cervical cancer transcriptome was obtained from eighty-nine
LACC samples and 6 non-tumor tissues. RNA quality was assessed
using the 18S:28S ratio. Hybridization targets and microarray prepro-
cessing were performed as previously reported [8]. The microarray
raw data are publicly available at the GEO database (Gene Expression
Omnibus, http://www.ncbi.nlm.nih.gov/geo/) with the accession num-
ber GSE56303.
2.3. Validation of gene expression by real-time RT-PCR
Oligonucleotide primers for the target genes were designed based
on the sequence data obtained from GenBank. The sequences of the
primer sets used for RT-qPCR veriﬁcation are listed in Supplemental
Table 1. Beta-actin was chosen as an endogenous control reference. RT
reactionswere performed according to the High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems) using total RNA from 20 LACC
samples and 10 normal cervix tissues. Real-time PCR was performed
using Luminaris Color HiGreen qPCR Master Mix (Thermo Scientiﬁc)
in StepOne Real-Time PCR System (Thermo Fisher Scientiﬁc), according
to the manufacturer's protocol. Two replicates were run for each gene.
The comparative Ct method (ΔΔCt) was used to quantify geneexpression, and the relative quantiﬁcation was calculated as 2−ΔΔCt
for the beta-actin housekeeping gene.
2.4. Validation of gene expression by immunochemistry
The expression of proteins in CC tissues implicated in the JAK-STAT,
NOTCH andmTOR-autophagy and cellular pathwayswas obtained from
the data deposited in the Human Protein Atlas [9]. The expression level
of each protein was classiﬁed as low, medium or high relative to that of
normal tissues.
2.5. Statistical analyses
To obtain a signiﬁcant list of genes aberrantly expressed in tumor tis-
sues in relation to normal counterparts, we employed signiﬁcance anal-
ysis of microarrays (SAM) software, which identiﬁes genes with
signiﬁcant changes in expression by assimilating a set of gene-speciﬁc
t tests. For each gene, a score is assigned based on its change in gene ex-
pression relative to the standard deviation of repeated measurements
for that gene. Genes with scores greater than the threshold are deemed
potentially signiﬁcant. We considered as positively or negatively regu-
lated genes thosewith a delta score N1.8 and less than−1.8, respective-
ly [10]. Retrieved genes were used to build a hierarchical cluster in
which the heat maps represent differences and similarities based on
the expression proﬁles (Fig. 1).
To identify the biological meaning of changes in gene expression,
positively regulated genes in tumor samples examined by the SAM
were submitted to the visualization tool Pathway Express (PE, a compo-
nent of Onto-Tools suite). This widely used bioinformatics tool allows
for the visualization of expression data in the context of KEGG biological
pathways. The importance of PE is that it generates an impact factor (IF)
of the entire pathway involved and a perturbation factor for each gene
involved in a speciﬁc signaling pathway, thus providing a clearer repre-
sentation of the alteration level for each biological pathway [11].
All data are expressed as themean± S.D. from two independent ex-
periments. Statistical analyses were performed using Student's t-test.
P b 0.05 (*) or P b 0.01 (**) was considered to indicate signiﬁcance.
3. Results
3.1. Patients
One hundred nine LACC patients were enrolled: LACC samples from
89 patients were subjected to hybridization microarray, and 20 were
used to validate the gene expression proﬁle obtained from the microar-
ray assay. The median age of the patients was 48 years (range, 29–
69 years). Most patients had been diagnosed with squamous cell carci-
noma (90.8%), andwere in stage IIB (60.5%) or IIIB (24.7%) at the time of
diagnosis (Table 1).
3.2. Gene expression proﬁle based on cluster analysis
To identify the differential gene expression proﬁle of LACC samples
compared with non-pathological cervical epithelia, we used the algo-
rithm SAM (http://www.stat.stanford.edu/~tibs/SAM), which identiﬁes
genes with signiﬁcant changes in expression using the cut-off values of
a delta score (score(d) ≥1.8 and ≤1.8 with a false discovery rate (FDR)
b10%).
Thus, we obtained a list of 13,065 genes (7530 up- and 5535 down-
regulated) signiﬁcantly altered in tumor samples versus their normal
counterparts. Hence, a hierarchical cluster was built using Genesis soft-
ware (Fig. 1). In general, the tumor samples showed a higher grade of
homology among them than the normal samples, which had a more
heterogeneous gene expression proﬁle. This observation suggests that,
although HPV infection is associated with several changes in the host
Fig. 1.Hierarchical cluster generated from 89 LACC and 6 non-tumor tissue samples. Cluster analysis of themicroarray data. Themicroarray datawere analyzed by the Genesis program [32]. The cluster shows 13,065 genes (7530 up- and 5535 down-
regulated). Each row represents a gene, whereas each column corresponds to a tissue sample, the color line above the tissue samples indicates the sample type: a) normal samples (blue) and b) tumor samples (red). The relative abundance of each
gene in the tissue correlates with the color intensity (red, induced; blue, repressed; white, no change). On the dendrogram, all six normal cervical samples clustered together, indicating their similarity based on the expression proﬁle.
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Table 1
Clinical characteristics of all patients.
Characteristic All patients (109) N (%)
Age 48
Range 29–69
Tumor stage (FIGO)
IB2 14 (12.0)
IIA 1 (0.91)
IIB 66 (60.5)
IIIA 1(0.91)
IIIB 27 (24.7)
Histology
Squamous cell carcinoma 99 (90.8)
Adenocarcinoma 10 (9.1)
Tumor size
≤4 cm 61 (55.04)
≥4 cm 48 (44.03)
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expression induced by carcinogenesis process is similar.3.3. Signaling pathway analysis
One of our main goals was to identify relevant cellular pathways
aberrantly expressed between tumor and normal tissues, whose
pharmacological inhibition as adjuvant therapy for LACC appears
reasonable based on available evidence. To that end, we used PE,
which is a component of Onto-Tools used to visualize expression
data in the context of the KEGG Biological Pathway. PE retrieves an
IF that can help to obtain a parameter of the alteration level in each
cellular pathway. Thus, we imported a list of 7530 genes signiﬁcantly
over-expressed in LACC samples compared with normal tissues into
the program to convert the expression data into pathway illustra-
tions. Thus, 93 IF top-rated signaling pathways were obtained in
tumor samples (Supplemental Table 2). The most affected cellular
pathways were cell adhesion molecules (CAMs) and adherens junc-
tions, which are involved in maintaining tissue architecture and
cell polarity. Both pathways are related to metastatic processes, a
ﬁnding that is expected because the clinical samples employed in
this study were obtained from invasive tumors. Nonetheless, of the
93 cellular pathways, we focused on those that offer an important
therapeutic potential such as the JAK-STAT, NOTCH and mTOR-au-
tophagy signaling pathways.
An important aspect of PE is that it calculates a perturbation factor or
perturbation index. The perturbation factor considers (i) the normal-
ized fold change of the gene and (ii) the number and amount of pertur-
bation genes downstream from it. The gene perturbation factor reﬂects
the relative importance of each differentially regulated gene [11]. In this
context, the JAK-STAT signaling pathway had sixty genes from 156with
a perturbation index from0.7 to 9.3. JAK2 (Janus Kinase), STAM1 (Signal
transducing adaptormolecules) and SOS1 (Son of sevenless homolog 1)
were selected for validation experiments by RT-qPCR and protein ex-
pression. Regarding the NOTCH signaling pathway, 32 genes of 48
were altered, with the perturbation index ranging from 0.4 to 2.0.
NOTCH1 (Notch homolog 1, translocation-associated), ADAM17
(ADAM metallopeptidase domain 17), PSEN1 (presenilin-1) and
NCSTN (nicastrin) were selected for validation experiments by RT-
qPCR and protein expression (Fig. 2). Regarding the mTOR-autophagy
signaling pathway, 32 of 52 genes were found to be deregulated with
a perturbation index ranging from1.3 to 12.5. Hence,we chose RPS6 (ri-
bosomal protein S6), STK11/LKB1 (serine/threonine kinase 11) and
MLTS8/GBL (MTORAssociated Protein, LST8Homolog) as validation tar-
gets (Fig. 3).3.4. Experimental validation of deregulated genes in CCLA tumor specimens
To validate the experimental data,we analyzed the expression levels
of individual genes of the JAK-STAT signaling pathway and the mTOR-
autophagy signaling pathway. Hence, using RT-qPCR, the expression
levels of NOTCH1, JAK2, STAM1, SOS1, ADAM17, PSEN1, NCSTN, RPS6,
STK11/LKB1 and MLTS8/GBL were evaluated in an independent cohort
consisting of 10 normal tissue cervix and 20 tumor tissues. As shown
in Fig. 4, all of the genes were over-expressed signiﬁcantly
(P N 0.0001). These results were consistent with the results obtained
from microarray analysis.
3.5. Immunohistochemical assessment of overexpressed genes with thera-
peutic potential
To further conﬁrm the gene expression levels obtained by microar-
ray experiments, we used immunohistochemical analysis to analyze
the expression of ten differentially expressed genes in tumors and
their normal counterparts. Therefore, we accessed the Human Protein
Atlas database (http://www.proteinatlas.org/), which has information
on protein expression in tumor and normal specimens. In agreement
with the microarray analysis data, positive immunostaining in tumor
samples was observed for JAK2 (10 positives from 12 analyzed tumor
tissues), STAM1 (11 positives from 12), SOS1 (9 positives from 12),
and NCSTN (9 positives from 10), and all of the tumor tissues exhibited
positivity for ADAM17, NOTCH, STK11/LKB1, PSEN1, RP61 and MLTS8/
GBL. It is worth noting that high- and/or medium-level expression
was present at a rate of ~75% in tumoral cells (Fig. 5).Most of these pro-
teins were localized in the cytoplasm and membrane except for the
SOS1, PER2 and STK11/LKB1 proteins, which were located in the nucle-
us. Thus, 91.7% of the samples were pathologically classiﬁed as squa-
mous cell carcinomas, and the remainder (8.3%) was classiﬁed as
adenocarcinomas (Fig. 5).
4. Discussion
Despite early screening programs for cancer detection and vaccines,
the impact on disease control has been limited for LACC diagnosed pa-
tients [12]. Concurrent chemo-radiotherapy followed by radical surgery
are the principal treatments for LACC; however, approximately 30–50%
of patients develop recurrent disease, which is a major cause of death
[2–7]. Moreover, some of these patients are not candidates to receive
cisplatin due to different co-morbidities [13]. In this respect, new target
therapies such as Ruxolitinib, Fedratinib and tocilizumab (JAK-STAT
pathway inhibitors), RO4929097, MK-0752, Anti-DLL4 mAb, OMP-
21M18 and OMP-59R (Notch pathway inhibitors), sirolimus,
temsirolimus, everolimus and ridaforolimus (mTOR-autophagy path-
way inhibitors) have been developed and they can be promising, but
further studies needed in LACC.
In an effort to provide genomic information with a special focus on
searching for promising therapeutic targets that could improve the clin-
ical outcome in LACC patients, we conducted a transcriptome analysis
on 89 LACC tumor samples because our main was to show differences
between normal tissues and cancer samples, obtaining 7530 genes
that were signiﬁcantly over-expressed. Next, gene annotation in biolog-
ically relevant databases resulted in 93 dysregulated signalingpathways
(Supplemental Table 2). JAK-STAT, NOTCH, andmTOR-autophagy path-
ways represents themost important pathways involved in cell survival,
differentiation, cell growth, progression and metastasis, and moreover
can be pharmacologically blocked. The data generated by The Cancer
Genome Atlas were used to analyze druggable cancer driver genes and
were identiﬁed as those linked to the Wnt, Notch, JAK/STAT, NF-κB
and MAPK signaling pathways, but, unfortunately, the data of CC have
been removed [14]. In this sense, JAK-STAT and NOTCH pathways re-
cently were identiﬁed by our research group as key pathways affected
in CC [15]. There is no information about the role of JAK-STAT pathway
Fig. 2. Schematic representation of JAK-STAT and NOTCH cellular pathways altered in locally cervical cancer patients. Some genes implicated in Notch signaling are well known to play
signiﬁcant roles in carcinogenesis and tumor progression. Cytokines and hormones bind to receptors to activate phosphorylation and SOS1-Ras-Raf-Erk signaling to induce
proliferation and differentiation. STAT molecules are activated and translocate to the nucleus where they bind to the promoter regions of target genes involved in anti-apoptosis and
the cell cycle. In addition, cells transmit the signal through ligands binding to them at the NOTCH receptors [1–4], which are cleaved by a member of the ADAM family (ADAM17 and
ADAM10) and gamma-secretase complex (PSEN1/2, NCSTN), leading to the release and nuclear transportation of NOTCH intracellular domain (NID), which regulates target gene
transcription [5]. The red arrows indicated higher gene expression, and the stars indicate genes validated by qPCR in LACC samples.
410 A.D. Campos-Parra et al. / Gynecologic Oncology 143 (2016) 406–413in cervical carcinogenesis or clinical association; we consider signiﬁcant
to focus on these poorly characterized pathways in order to increase the
current knowledge about them. Respecting to Notch pathway, despite
of some reports showing its role in cervical carcinogenesis [16], there
is no information about the importance of this pathway as a therapeuticFig. 3. Schematic representation of themTOR-autophagy cellular pathways altered in locally cer
progression, and many of its components are ampliﬁed in human cancers. Insulin, hormon
destabilizes the TSC1/2 complex, promoting mTOR activation. The complex mTOR, MLTS8/GB
the complex mTOR, MLTS8/GBL and Rictor are AKT and PKC, which regulate cell survival. In c
(ULK1/2). STK11/LKB1 modulates AMPK activity [6]. The red arrows indicate higher gene exprtarget in locally advanced cervical cancer (LACC) patients. In this sense,
we describe new molecular pathways susceptible to be used as thera-
peutic targets in the treatment of patients with cervical cancer. Addi-
tionally, the mTOR-related pathways represent the most important
pathways involved in progression, invasiveness and metastasis, andvical cancer patients. mTOR-autophagy signaling is implicated in cancer development and
es and growth factors activate the PI3K/Akt signaling cascade. Akt phosphorylates and
L and Raptor phosphorylates S6 (RPS6) to modulate cell growth. Downstream targets of
ontrast, mTOR negatively regulates autophagy by inhibiting Atgs such as Atg13 and Atg1
ession, and the stars indicate genes validated by qPCR in LACC samples.
Fig. 4. Analysis of the relative expression of dysregulated genes in LACC and normal cervix tissue. The expression patterns of genes by RT-qPCR were determined as described in the
Materials and Methods section. Statistical analysis to compare the mRNA expression levels between normal and tumor tissues was performed using an unpaired two-tailed t-test. A)
Representative genes from the JAK-STAT signaling pathway. B) Representative genes from the NOTCH signaling pathway. C) Representative genes from the mTOR signaling pathway.
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Fig. 5. Immunohistochemical analysis of overexpressed proteins in LACC. A) The datawere collected from theHuman Protein Atlas for normal and cervical carcinoma tissues. All images of
immunohistochemistry-stained cancer tissues are available as high-resolution images in the cancer tissue atlas. B) Graphical representation of the number of samples analyzed according
to the level of expression. T (Tumor Tissue) and N (Normal tissue).
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clinical relevance is limited whereby their study can provide new and
important clinical information to patients with advanced disease.
In our ﬁndings, we have shown the consistent overexpression of key
molecules of the JAK-STAT, NOTCH and mTOR-autophagy pathways by
microarray, qRT-PCR and immunohistochemistry in LACC. To our
knowledge, this is the ﬁrst study where the messenger RNA expression
of SOS1, STAM1, MLST8/GBL and gamma-secretase complex (PSEN1
and NSCTN) was analyzed in CC.
Previously, it has been reported in prostate carcinomas and ad-
vanced ovarian cancer that SOS1 overexpression correlates with cancer
progression andwith a shorter survival, indicating that its dysregulation
is an essential requirement for tumorigenesis [17]. We noticed that
MLTS8/GBLmRNA and proteinwere overexpressed in CC, its expression
has been evaluated in other tumors, such as prostate and colon cancer,
and contributes to tumor growth and invasion; in addition, strong pro-
tein expression has been observed in invasive cancer lesions [18].
RPS6/p70S6K is a key protein of mTOR signaling (Fig. 3), which has
been reported to be increased in cervical squamous cell carcinomas,
and the overexpression was signiﬁcantly associated with the occur-
rence of distant metastasis, similar to our results [19]. Temsirolimus,
everolimus and ridaforolimus are mTOR inhibitors that have been eval-
uated for phase II trials in patients with advanced or recurrent gyneco-
logical cancer, temsirolimus has been shown amodest clinical beneﬁt in
37 metastatic LACC patients, most patients experienced stable disease,
suggesting that patient preselection with prognosis biomarkers would
be very useful [20]. As expected, we found that the expression level of
messenger RNA and protein from STK11/LKB1, RPS6 and MLTS8/GBL
was upregulated, due to the overexpression ofmTOR proteins that is as-
sociated with an increasingly aggressive clinical course and that has
been reported to be useful for targeted therapy [21]. Unexpectedly,
the tumor suppressor gene STK11/LKB1 was over-expressed, but our
ﬁndings are consistent with those of a previous report showing that
STK11/LKB1 expression is higher in cervical tumors than in normal tis-
sues [22]. Moreover, LKB1 is mutated in at least 2% of cervical tumors;
therefore, over-expression of the gene could be a mechanism to attenu-
ate the tumor phenotype [23]. Similarly, stronger LKB1 expression in co-
lorectal carcinomas than in normal mucosa has been reported [24].Similar to our results, JAK2 overexpression has been reported in
breast inﬁltrating ductal carcinoma, an aggressive and rare tumor type
with a poor prognosis, andwas associated with themechanism of resis-
tance after neoadjuvant chemotherapy [25]. JAK2 inhibitors such as
Ruxolitinib, fedratinid have been shown that are well-tolerated and
they improve overall survival in advanced pancreatic adenocarcinoma,
advanced ovarian cancer and myeloﬁbrosis patients [26].
Concordant with our results, has been reported that NOTCH1 and
ADAM17 expression is signiﬁcantly higher in CC than in normal tissues;
these proteins have been signiﬁcantly associated with tumor differenti-
ation, aggressive progression and poor prognosis, suggesting that
NOTCH signaling may be involved in CC progression [26–27]. The use
of the NCSTN antibody in breast cancer cells decreased NOTCH1 expres-
sion and reduced the invasive capacity of the cells [27]. In addition,
gamma secretase (PSEN and NSCTN) inhibitors have been shown to
have the potential to sensitize breast cancer cells to chemotherapeutics
that block chemoresistance [28,29]. In CC patients, treatment with
RO4929097 (gamma secretase inhibitor) plus capecitabine to overcome
chemotherapy resistance exhibited a clinical beneﬁt and tolerance to
side effects [30,31].
This work provides information regarding signaling pathways with
promising therapeutic targets, with these ﬁndings, it is reasonable to
speculate that the overexpression of key molecules of the JAK-STAT,
NOTCH and mTOR pathways make them potential molecular therapeu-
tic targets, although a limitation of our work was to validate the micro-
array results in only 20 LACC samples, these will need to improve
further in a large set of LACC samples.
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